Salix Pharmaceuticals, Ltd. Share Price

Stocks

17/15/17	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
17/15/17	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
17/15/17	Wall St. bounces as dollar drops, Fed worries ease	RE
16/15/16	Endo : withdraws offer for Salix	RE
12/15/12	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/15/05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
24/15/24	Shire : buys Meritage Pharma for at least $70 million	RE
24/15/24	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
24/15/24	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
23/15/23	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
22/15/22	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

12/15/12	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
03/15/03	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
27/15/27	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
26/15/26	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 1.5% Convertible Senior Notes Due 2019	BU
26/15/26	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 2.75% Convertible Senior Notes Due 2015	BU

02/15/02	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
30/15/30	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
17/15/17	Le recul du dollar a favorisé le rebond de Wall Street
16/15/16	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
16/15/16	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	01/01/2018
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
MERCK & CO., INC.	-0.19%	+1.49%	+81.01%	+36.60%	36TCr
MERCK KGAA	-1.22%	-1.37%	+20.62%	-21.54%	6.56TCr
HALOZYME THERAPEUTICS, INC.	+2.53%	+5.09%	+48.33%	+186.72%	1.24TCr
KYOWA KIRIN CO., LTD.	-0.29%	+2.27%	-5.37%	-16.54%	760.29Cr
SK BIOPHARMACEUTICALS CO., LTD.	-1.89%	-6.83%	-27.65%	-14.90%	449.16Cr
YUHAN CORPORATION	-2.06%	-3.80%	-34.68%	+5.56%	418.7Cr
BETTA PHARMACEUTICALS CO., LTD.	+1.48%	+2.36%	-31.20%	-13.91%	291.9Cr
SUPERNUS PHARMACEUTICALS, INC.	-2.14%	+0.74%	-6.25%	+43.69%	249.48Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.41%	-0.71%	-28.25%	-33.78%	193.24Cr
Average	-0.52%	+0.50%	+1.84%	+19.10%	5.16TCr
Weighted average by Cap.	-0.57%	+1.38%	+66.47%	+30.19%